Atomic AI is a South San Francisco biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery. Its platform pairs in-house wet-lab chemical-mapping data with deep learning models - including ATOM-1, a foundation model for RNA structure, and PARSE, its RNA structure exploration platform - to find structured, ligandable RNA motifs and design selective small molecules and RNA-based medicines for targets long considered undruggable.
Raphael Townshend is the founder and CEO of Atomic AI, a South San Francisco biotech fusing machine learning with structural biology to make RNA a druggable target. A Stanford AI Lab PhD who trained 18 known RNA structures into a model that beat far larger labs, he turned a Science cover paper into a company that has raised $42M to build ATOM-1, a foundation model for RNA structure. Forbes 30 Under 30, ex-DeepMind AlphaFold, ex-Google.